Tags · Evidence
effect size
Magnitude, not just direction or significance.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis
214 topics · page 6 of 8
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
|
+71 | 80 | 38k | 11mo |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |
|
Coming back to: An 18-month record including the parts that went badly
Posting this under the heading it deserves: An 18-month record including the parts that went badly Everything below is what sits behind that. Asking about 18-month record on behalf of the question I keep…
|
+83 | 89 | 52k | 12mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
2 | 1.9k | 12mo | |
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…
|
+27 | 31 | 671 | 12mo |
|
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. The question about Reading a combination trial that I…
|
+39 | 43 | 7.3k | 12mo |
|
Regression to the mean in progress reports
On the subject in the title: Regression to the mean in progress reports Working notes rather than a conclusion. Something about regression does not reconcile and I would like a second pair of eyes before I…
|
+30 | 34 | 49k | 12mo |
|
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…
|
+12 | 16 | 50k | 12mo |
|
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on CagriSema phase 2 combination paper.…
|
+74 | 79 | 2.3k | 13mo |
|
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
|
+48 | 53 | 31k | 13mo |
|
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Random versus fixed effects, and specifically the version of it that the…
|
+16 | 20 | 22k | 13mo |
|
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Posting a small dataset on SURMOUNT-4 and…
|
+58 | 64 | 17k | 13mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
|
+128 | 142 | 38k | 13mo |
|
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
+15 | 19 | 4.4k | 13mo |
|
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+65 | 71 | 4.6k | 13mo |
|
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Something about individual participant data versus aggregate does not…
|
+30 | 34 | 64k | 14mo |
|
Pre-registering a personal experiment, seriously
Pre-registering a personal experiment, seriously — setting out what I have, and where I think it stops being reliable. A narrow question about pre-registering a personal experiment, deliberately narrow,…
|
+96 | 119 | 58k | 14mo |
|
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…
|
+117 | 128 | 7.2k | 14mo |
|
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because a question about…
|
2 | 41k | 14mo | |
|
Second pass at: Designing a personal experiment that could change your mind
Second pass at: Designing a personal experiment that could change your mind Writing it up because I had to work it out twice and would rather nobody else did. The question about Designing a personal…
|
+39 | 44 | 632 | 14mo |
|
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. I was wrong about critiquing an observational claim in a thread…
|
2 | 6.9k | 14mo | |
|
Coming back to: A critique that turned out to be unfair, retracted by its author
A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about critique, three…
|
2 | 1.3k | 14mo | |
|
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about criticising the method without criticising in a…
|
+55 | 61 | 60k | 15mo |
|
Journal club: STEP 4 and what a withdrawal design can prove — one year on
Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 4 ( JAMA , 2021). Please read…
|
+56 | 62 | 34k | 15mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |
|
Follow-up: Journal club: the retatrutide phase 2 obesity paper
On the subject in the title: Journal club: the retatrutide phase 2 obesity paper Working notes rather than a conclusion. A follow-up question about retatrutide phase 2 obesity paper that I did not know to ask…
|
+20 | 24 | 8.7k | 16mo |
|
About the Progress reports category
Longitudinal self-reports with the method stated. Scales, tape measures, and their error bars. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
|
4 | 139 | 16mo | |
|
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about cagrilintide alone…
|
+93 | 108 | 35k | 16mo |